8-K current report · filed Jul 6, 2026

Prestige Consumer Healthcare Inc. (PBH) 8-K Current Report: July 6, 2026

Item 1.01Item 2.03Item 7.01Item EX-99.1PBH overview

Short answer

Prestige Consumer Healthcare Inc. (PBH) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $95.0 million incremental term-loan capacity for LaCorium Acquisition financing.

Prestige Consumer Healthcare Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $95.0 million incremental term-loan capacity for LaCorium Acquisition financing
  • Proceeds may also cover transaction fees and expenses
  • Acquisition targets five Australian companies, expanding Prestige’s international portfolio
  • Amendment increases leverage and future interest obligations, with definitive terms to appear in the Form 10-Q exhibit

Item 2.03 · Creation of a Direct Financial Obligation

  • $95 million borrowed under amended credit facility on closing date
  • Proceeds funded LaCorium Acquisition plus transaction fees and expenses
  • New borrowing increases leverage and debt-service obligations for Prestige Consumer Healthcare

Item 7.01 · Regulation FD Disclosure

  • $400 million senior unsecured notes offering, due 2034, signaling long-term financing activity
  • LaCorium Acquisition completed, expanding Prestige Consumer Healthcare’s portfolio
  • Note pricing announced alongside acquisition completion, linking financing to the transaction timeline
  • Full offering and acquisition terms in Exhibits 99.1 and 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Proposed $400 million senior unsecured notes due 2034, guaranteed by PBH and certain domestic subsidiaries
  • Proceeds plus cash on hand targeted to redeem all $400 million 5.125% notes due 2028
  • Refinancing extends maturity from 2028 to 2034, reducing near-term debt refinancing risk
  • 2028 notes redemption priced at 100.0% of principal plus accrued unpaid interest
  • New offering completion requires at least $400 million issuance unless Prestige Brands waives the financing condition

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Prestige Consumer Healthcare Inc. 8-K filings

Get the next PBH 8-K as it lands

Follow PBH for push alerts, or ask the research agent what this filing means.